TAGRISSO TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

OSIMERTINIB (OSIMERTINIB MESYLATE)

Saadav alates:

ASTRAZENECA CANADA INC

ATC kood:

L01EB04

INN (Rahvusvaheline Nimetus):

OSIMERTINIB

Annus:

40MG

Ravimvorm:

TABLET

Koostis:

OSIMERTINIB (OSIMERTINIB MESYLATE) 40MG

Manustamisviis:

ORAL

Ühikuid pakis:

30

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANTINEOPLASTIC AGENTS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0158250001; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2016-07-05

Toote omadused

_ _
_TAGRISSO_
_®_
_ (osimertinib) Product Monograph. _
_Page 1 of 62_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
TAGRISSO®
osimertinib tablets
Tablets, 40 mg and 80 mg osimertinib (as osimertinib mesylate), Oral
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor,
L01XE35
AstraZeneca Canada Inc.
1004 Middlegate Road, Suite 5000
Mississauga, Ontario
Canada, L4Y 1M4
www.astrazeneca.ca
Date of Initial Authorization:
JUL 05, 2016
Date of Revision:
JAN 02, 2024
Submission Control Number: 277035
TAGRISSO® is a registered trademark of AstraZeneca AB, used under
license by AstraZeneca Canada Inc.
©AstraZeneca Canada Inc. 2023
_ _
_TAGRISSO_
_®_
_ (osimertinib) Product Monograph. _
_Page 2 of 62_
RECENT MAJOR LABEL CHANGES
1 INDICATIONS
01/2021
1 INDICATIONS, 1.2 Geriatrics
01/2021
4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
01/2021
4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose and
Dosage Adjustment
03/2023
7 WARNINGS AND PRECAUTIONS
01/2024
7 WARNINGS AND PRECAUTIONS, 7.1.4 Geriatrics
01/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.........................................................................................................
2
TABLE OF CONTENTS
...........................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................................................
4
1
INDICATIONS
..........................................................................................................................
4
1.1
Pediatrics
...........................................................................................................................4
1.2
Geriatrics
............................................................................................................................4
2
CONTRAINDICATIONS
..........................................